Illumina Unveils $395 TruPath Genome, Doubles Throughput to 16 Genomes/Day
Illumina launched TruPath Genome at a $395 list price, doubling throughput to 16 genomes per day with 30x coverage, 98% gene phasing accuracy and DRAGEN-enhanced variant detection. Broad Clinical Labs and over 30 early-access customers have adopted the system for rare disease research following AGBT presentations.
1. Product Launch and Pricing
Illumina introduced TruPath Genome with a $395 USD list price inclusive of consumables and analysis, offering a streamlined workflow that eliminates traditional library prep and delivers 16 whole genomes per day at an industry-standard depth of at least 30x coverage.
2. Technical Innovations
TruPath Genome leverages on-flow cell library preparation, patterned flow cell technology and DRAGEN algorithms to achieve 98% gene phasing, enhanced variant calling in difficult-to-map regions, structural variant detection, and short tandem repeat resolution within minutes of hands-on time.
3. Early Adopters and Trials
Broad Clinical Labs, GeneDx, Rady Children’s Hospital and Baylor College of Medicine are among more than 30 early-access customers piloting TruPath Genome, while University Medical Center Utrecht and University of Exeter trials demonstrated improved resolution of complex genomic regions and non-invasive prenatal diagnostic capabilities.
4. Market Outlook
By offering near-double throughput over competing long-read methods and comprehensive whole-genome insights at a competitive price point, TruPath Genome positions Illumina to capture increased clinical research and rare disease sequencing market share, potentially boosting future revenue growth.